The campaign aimed to position Faron as a leading innovator in immunotherapy and raise awareness of its pioneering work in clinical cancer research. It sought to establish CEO Juho Jalkanen as a recognised expert in therapeutic treatments, highlighting his leadership in developing novel, life-saving cancer therapies. The campaign focused on showcasing Faron’s commitment to tackling leukaemia, one of the deadliest cancers, through groundbreaking research. A key milestone was the release of the promising Phase 2 trial results for Bexmarilimab (Bex), especially in patients with relapsed or hard-to-treat blood cancers. When combined with azacitidine, bex more than doubled median survival rates. These results were presented for the first time at the European Haematology Association Congress.